WallStreetZen

NASDAQ: CYTK
Cytokinetics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for CYTK

Based on 6 analysts offering 12 month price targets for Cytokinetics Inc.
Min Forecast
$40.00+8.37%
Avg Forecast
$54.00+46.3%
Max Forecast
$75.00+103.2%

Should I buy or sell CYTK stock?

Based on 6 analysts offering ratings for Cytokinetics Inc.
Strong Buy
Strong Buy
4 analysts 66.67%
Buy
2 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

CYTK stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Mizuho
Top 37%
64
Strong BuyMaintains$54.00+46.30%2021-12-01
HC Wainwright & Co.
Top 12%
89
BuyMaintains$62.00+67.98%2021-11-04
Morgan Stanley
Top 37%
64
Strong BuyMaintains$45.00+21.92%2021-10-08
Jefferies
Top 42%
59
Strong BuyInitiates Coverage On$75.00+103.20%2021-10-07
Barclays
Bottom 14%
14
Strong BuyMaintains$40.00+8.37%2021-07-20
Needham
Bottom 3%
3
BuyMaintains$48.00+30.05%2021-07-19
Anonymous
Morgan Stanley
Strong BuyMaintains$35.00-5.17%2021-04-19

1 of 1

Forecast return on equity

Is CYTK forecast to generate an efficient return?
Company
-117.9%
Industry
21.88%
Market
37.5%
CYTK's Return on Equity is forecast to be low in 3 years (-117.9%); analysts are not confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is CYTK forecast to generate an efficient return on assets?
Company
-35.48%
Industry
6.66%
CYTK is forecast to generate lower Return on Assets (-35.48%) than the US Biotechnology industry average (6.66%)
Forecast

CYTK earnings per share forecast

What is CYTK's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
-$3.02-2.58%
Avg 2 year Forecast
-$3.17+2.26%
Avg 3 year Forecast
-$2.88-7.1%

CYTK revenue forecast

What is CYTK's revenue in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$21.1M-2.09%
Avg 2 year Forecast
$40.0M+85.64%
Avg 3 year Forecast
$71.8M+233.04%
CYTK's revenue is forecast to grow at an exceptional rate of 47.37% per year
Forecast

CYTK revenue growth forecast

How is CYTK forecast to perform vs Biotechnology companies and vs the US market?
Company
47.37%
Industry
30.03%
Market
10.08%
CYTK's revenues are forecast to grow faster (47.37% per year) than the US Biotechnology industry average (30.03%)
Forecast
CYTK's revenues are forecast to grow faster (47.37% per year) than the US market average (10.08%)
Forecast

Cytokinetics Stock Forecast FAQ

Is Cytokinetics Stock a good buy in 2021, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: CYTK) stock is to Strong Buy CYTK stock.

Out of 6 analysts, 4 (66.67%) are recommending CYTK as a Strong Buy, 2 (33.33%) are recommending CYTK as a Buy, 0 (0%) are recommending CYTK as a Hold, 0 (0%) are recommending CYTK as a Sell, and 0 (0%) are recommending CYTK as a Strong Sell.

What is CYTK's earnings growth forecast for 2021-2023?

(NASDAQ: CYTK) Cytokinetics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 6.78%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.37%.

Cytokinetics's earnings in 2021 is -$228,674,000.On average, 5 Wall Street analysts forecast CYTK's earnings for 2021 to be $-253,326,518, with the lowest CYTK earnings forecast at $-266,747,791, and the highest CYTK earnings forecast at $-241,582,905. On average, 5 Wall Street analysts forecast CYTK's earnings for 2022 to be $-265,908,961, with the lowest CYTK earnings forecast at $-301,978,631, and the highest CYTK earnings forecast at $-195,447,280.

In 2023, CYTK is forecast to generate $-241,582,905 in earnings, with the lowest earnings forecast at $-291,912,676 and the highest earnings forecast at $-191,253,133.

What is CYTK's revenue growth forecast for 2021-2023?

(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 47.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.03%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Cytokinetics's revenue in 2021 is $21,550,000.On average, 5 Wall Street analysts forecast CYTK's revenue for 2021 to be $1,769,930,308, with the lowest CYTK revenue forecast at $1,280,892,692, and the highest CYTK revenue forecast at $1,962,861,100. On average, 4 Wall Street analysts forecast CYTK's revenue for 2022 to be $3,355,737,535, with the lowest CYTK revenue forecast at $1,761,542,013, and the highest CYTK revenue forecast at $7,047,845,711.

In 2023, CYTK is forecast to generate $6,020,279,537 in revenue, with the lowest revenue forecast at $2,348,722,684 and the highest revenue forecast at $10,417,423,933.

What is CYTK's forecast return on assets (ROA) for 2021-2024?

(NASDAQ: CYTK) forecast ROA is -35.48%, which is lower than the forecast US Biotechnology industry average of 6.66%.

What is CYTK's Price Target?

According to 6 Wall Street analysts that have issued a 1 year CYTK price target, the average CYTK price target is $54.00, with the highest CYTK stock price forecast at $75.00 and the lowest CYTK stock price forecast at $40.00.

On average, Wall Street analysts predict that Cytokinetics's share price could stay at $54.00 by Dec 1, 2022. The average Cytokinetics stock price prediction forecasts a potential downside of N/A from the current CYTK share price of $36.91.

What is CYTK's Earnings Per Share (EPS) forecast for 2021-2023?

(NASDAQ: CYTK) Cytokinetics's current Earnings Per Share (EPS) is -$3.10. On average, analysts forecast that CYTK's EPS will be $-3.02 for 2021, with the lowest EPS forecast at $-3.18, and the highest EPS forecast at $-2.88. On average, analysts forecast that CYTK's EPS will be $-3.17 for 2022, with the lowest EPS forecast at $-3.60, and the highest EPS forecast at $-2.33. In 2023, CYTK's EPS is forecast to hit $-2.88 (min: $-3.48, max: $-2.28).

What is CYTK's forecast return on equity (ROE) for 2021-2024?

(NASDAQ: CYTK) forecast ROE is -117.9%, which is considered weak.
©2021 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.